10-KPeriod: FY2006

QUEST DIAGNOSTICS INC Annual Report, Year Ended Dec 31, 2006

Filed March 1, 2007For Securities:DGX

Summary

Quest Diagnostics Incorporated, a leading provider of diagnostic testing, information, and services, reported $6.3 billion in net revenues for the fiscal year ended December 31, 2006, processing approximately 151 million requisitions. The company operates a substantial nationwide network of laboratories and patient service centers, positioning itself as a key player in the estimated $45 billion U.S. clinical laboratory testing market. Key strategic initiatives include organic growth driven by quality, access, and innovation, particularly in higher-growth areas like gene-based testing and information technology solutions (e.g., Care360™). Quest Diagnostics has also been active in acquisitions, notably the recent purchases of HemoCue (near-patient testing), Focus Diagnostics (infectious and immunologic disease testing), and Enterix (colorectal cancer screening). However, the company faces significant challenges, including reimbursement pressures from government and private payers, increased competition, and the ongoing integration of acquired businesses. A notable recent development is the termination of its national contract with United Healthcare, expected to reduce revenue growth in 2007.

Key Highlights

  • 1Quest Diagnostics generated $6.3 billion in net revenues for the fiscal year 2006, processing approximately 151 million test requisitions.
  • 2The company is a leading provider of diagnostic testing services, operating a large network of laboratories and patient service centers across the United States.
  • 3Key growth strategies include organic expansion driven by quality and innovation, with a focus on high-growth areas such as gene-based testing and information technology solutions.
  • 4Recent strategic acquisitions include HemoCue (near-patient testing), Focus Diagnostics (infectious/immunologic disease testing), and Enterix (colorectal cancer screening), aimed at expanding market reach and service offerings.
  • 5The company is experiencing significant challenges from healthcare payer dynamics, including reimbursement pressures and the termination of a major contract with United Healthcare, which is projected to impact 2007 revenue growth.
  • 6Quest Diagnostics emphasizes quality assurance, with efforts to implement Six Sigma and Lean processes, and holds ISO certifications for some of its facilities.
  • 7The company is navigating a complex regulatory environment, including CLIA, HIPAA, and various federal and state laws governing healthcare operations and reimbursement.

Frequently Asked Questions

Quest Diagnostics is a leading provider of diagnostic testing, information, and services. It operates a nationwide network of laboratories and patient service centers and is a significant player in the U.S. clinical laboratory testing market, which is estimated to be worth $45 billion annually.

The company's growth strategy focuses on both organic growth and acquisitions. Organic growth is driven by a commitment to high-quality services, unparalleled access and distribution, a comprehensive test menu, and innovation in areas like gene-based testing and information technology solutions (Care360™). Acquisitions, such as HemoCue and Focus Diagnostics, are aimed at expanding into new markets like near-patient testing and strengthening existing service lines.

Key challenges include significant pressure on reimbursement rates from government and private payers, consolidation among healthcare insurers leading to increased bargaining power, intense competition from various laboratory providers (including hospital-affiliated labs), and the complexities of integrating acquired businesses. The termination of its contract with United Healthcare is a notable short-term challenge impacting projected revenue growth.

Quest Diagnostics operates under a comprehensive compliance program and is subject to extensive federal and state regulations, including CLIA, HIPAA, and laws related to healthcare fraud and abuse. The company actively investigates compliance issues, reports any overpayments to the government, and cooperates with ongoing investigations. It also faces risks related to potential changes in FDA regulations concerning laboratory-developed tests.